Photo credit: Eli Lilly
Dave Ricks is leading one of the world’s most important pharmaceutical companies, Eli Lilly. And he’s doing it at the exact moment the company is redefining the global drug market. Under his watch, Lilly has become a near–trillion-dollar giant thanks to its blockbuster GLP-1 drugs for diabetes and weight loss; treatments that are reshaping public health, consumer behavior, and even national policy, not to mention my waistline.
Ricks also sits at the center of the biggest shift in U.S. healthcare, namely Medicare’s move to cover obesity drugs, which could open access for tens of millions of people and massively expand the market for Lilly’s upcoming pill, orforglipron (dude, call me the next time you’re naming something). He’s already signaling that this policy change will “open things up pretty wide,” giving Lilly enormous influence over pricing, access, and competition.
On top of that, he’s overseeing huge investments in U.S. manufacturing and advanced R&D. That includes everything from new plants to AI-powered drug discovery, all of which is cementing Lilly’s and subsequently Rick’s role as a national economic and scientific force.
